| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CNT1; HCNT1; URCTU |
| WB Predicted band size | 72 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC28A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SLC28A1抗体的参考文献示例(文献信息为模拟生成，仅作格式参考)：
1. **标题**: "Characterization of SLC28A1 (CNT1) protein expression in human tissues using a novel monoclonal antibody"
**作者**: Smith A, et al.
**摘要**: 通过开发特异性抗SLC28A1的单克隆抗体，研究证实该蛋白在肝脏、肾脏及肠道中高表达，并用于免疫组化分析其亚细胞定位。
2. **标题**: "Role of concentrative nucleoside transporter 1 (SLC28A1) in gemcitabine uptake"
**作者**: Zhang L, et al.
**摘要**: 利用SLC28A1抗体进行Western blot和免疫荧光，发现胰腺癌细胞中SLC28A1表达水平与吉西他滨药物敏感性呈正相关。
3. **标题**: "SLC28A1 genetic variants and protein abundance in colorectal cancer"
**作者**: Kim H, et al.
**摘要**: 通过免疫组化结合抗SLC28A1抗体，揭示结直肠癌组织中SLC28A1蛋白表达降低与患者预后不良相关。
4. **标题**: "Validation of SLC28A1 antibody for flow cytometry analysis in immune cells"
**作者**: García-Ruiz C, et al.
**摘要**: 验证商业化多克隆SLC28A1抗体在流式细胞术中的应用，确认其在T淋巴细胞中的功能性表达与核苷酸代谢调控有关。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
The SLC28A1 gene encodes concentrative nucleoside transporter 1 (CNT1), a protein belonging to the solute carrier family 28 (SLC28), which facilitates sodium-dependent uptake of nucleosides and nucleoside analog drugs across cell membranes. Primarily expressed in the kidneys, liver, intestines, and certain immune cells, SLC28A1 plays a critical role in mediating cellular absorption of pyrimidine nucleosides (e.g., uridine, thymidine) and clinically relevant therapeutics like anticancer agents (e.g., gemcitabine) or antiviral drugs (e.g., zalcitabine). Its function impacts nucleotide biosynthesis, drug pharmacokinetics, and cellular responses to nucleoside-based therapies.
SLC28A1-specific antibodies are immunological tools designed to detect and quantify CNT1 protein expression in research applications. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study tissue-specific expression patterns, subcellular localization, and regulatory changes in disease contexts. Validated antibodies help explore SLC28A1's involvement in cancer drug resistance, genetic disorders of nucleoside metabolism, or interactions with pharmacological agents.
When selecting SLC28A1 antibodies, specificity and cross-reactivity with other SLC28 isoforms (e.g., CNT2/SLC28A2. CNT3/SLC28A3) must be confirmed via knockout controls or peptide-blocking assays. High-quality antibodies are essential for elucidating CNT1's physiological roles and its potential as a biomarker or therapeutic target. Researchers should verify antibody performance in their experimental systems using appropriate positive controls (e.g., tissues with known CNT1 expression) and cite peer-reviewed validation data.
×
